pCPA completes ELAHERE negotiations; public-plan decisions still ahead

Negotiations between the pan-Canadian Pharmaceutical Alliance (pCPA) and AbbVie for ELAHERE (mirvetuximab soravtansine) have concluded with a signed letter of intent (LOI), the parties announced this week. AbbVie’s announcement was dated October 21; the pCPA negotiation tracker lists the file as “Concluded with an LOI.” That is a significant reimbursement milestone, but it is not the same as an immediate listing on every public drug plan.

Where the process stands

ELAHERE is a prescription antibody-drug conjugate approved by Health Canada in 2025 for adults with folate receptor-alpha (FRα)-positive, platinum-resistant epithelial ovarian, fallopian tube or primary peritoneal cancer who have received one to three prior systemic treatment regimens. The approved population and specific treatment requirements should always be checked against the Canadian product monograph and the treating oncology team’s plan.

In the pCPA process, the LOI records mutually agreed terms following negotiations. The pCPA’s status page is the clearest public signal of the file’s current stage. Participating provincial and territorial programs still determine whether and how a drug is listed, including any plan-specific eligibility, prior-authorization requirements and implementation timing. The terms themselves do not establish that every eligible patient can now obtain publicly funded treatment.

Canada’s Drug Agency published a reimbursement recommendation for ELAHERE before the new agreement. That assessment is part of the wider review pathway, not a substitute for provincial or territorial listing decisions. The new LOI should therefore be understood as one step between clinical and reimbursement review and possible plan coverage. Patients may still need to confirm whether their province or territory has published criteria and when those criteria take effect.

Why this matters in practice

For oncology pharmacists, a reimbursement milestone can trigger questions well before a drug appears on a local formulary. Patients and care teams may ask whether the treatment is covered, whether a biomarker result is required, what prior treatment history qualifies, and what paperwork is needed. Those questions should be answered from the current Canadian monograph and the relevant public plan’s own notice—not inferred from the manufacturer’s announcement alone.

Practice guidance for pharmacists

• Check the pCPA negotiation tracker and the relevant provincial or territorial formulary separately. Do not tell a patient that ELAHERE is publicly covered solely because negotiations have concluded with an LOI.
• Use the Canadian product monograph and oncology prescriber’s plan to verify the approved indication, FRα status, prior treatment history, dose and other clinical requirements before discussing access pathways.
• When a public plan posts criteria, confirm the effective date, eligible population, prior-authorization process, required clinical documentation and any renewal conditions directly from that plan.
• For patients waiting on a listing or an authorization decision, explain what is known and what remains pending; avoid promising a coverage date or reimbursement outcome that has not been published by the plan.
• Coordinate with the oncology team and specialty pharmacy on the practical steps that may affect treatment timing, including biomarker documentation, benefit verification, dispensing arrangements and adverse-effect monitoring.

For now, the news is that negotiations have reached the LOI stage. The next concrete access signal will be a provincial or territorial plan decision, with its own published criteria and timing.